常规分割大体积头颈部再程放疗:MLC机器人技术可行性研究
本研究纳入8例接受治愈性质子治疗的复发或第二原发头颈癌患者,靶区体积>30 cm³,比较MLC-based CyberKnife与质子束治疗的剂量学表现。两种方式靶区覆盖与均匀性相似,质子治疗适形指数更优,而MLC-based CyberKnife可提供高剂量梯度实现快速剂量跌落并保护危及器官,常规分割MLC-based CyberKnife可作为大体积头颈部再程放疗的竞争性选择。
要点
- MLC-based CyberKnife与质子治疗在靶区覆盖和均匀性上相似。
- 质子治疗适形指数更优(0.6 vs 0.5,p=0.04)。
- MLC-based CyberKnife可提供高剂量梯度,快速剂量跌落保护危及器官。
核心结论
- MLC-based CyberKnife在大体积头颈部再程放疗中展现出可行的剂量学性能,可作为质子治疗的竞争性替代方案,值得进一步临床研究。
研究设计与样本
- 可行性研究,纳入2011至2015年接受治愈性质子治疗、靶区体积>30 cm³的复发或第二原发头颈癌患者8例,比较MLC-based CyberKnife计划与质子束治疗计划的剂量学指标。
主要发现
- 8例患者肿瘤部位包括唾液腺、咽部(口咽、下咽、咽后)和鼻腔鼻窦;5例接受多野优化调强质子治疗,3例接受被动散射质子治疗。
- 中位剂量67 Gy(范围60-70),32次(范围30-35);高危PTV中位体积45.4 cm³(范围2.4-130.2 cm³), elective PTV中位体积91.9 cm³(范围61.2-269.7 cm³)。
- 靶区平均覆盖MLC-based CyberKnife 98.3% vs 质子治疗96.2%,PTV最大剂量均值均为111%(p=0.2),PTV平均剂量均值均为104%。
- 平均适形指数质子治疗更优(0.6 vs 0.5,p=0.04);均匀性和梯度指数相似;单次治疗时间质子治疗17分钟 vs MLC-based CyberKnife 18分钟(p=0.7)。
- 个案分析显示两种计划均能良好保护危及器官,部分临床场景MLC-based CyberKnife表现更优,另一些场景质子治疗更优。
关键数值与推荐
- 靶区覆盖:MLC-based CyberKnife平均98.3%,质子治疗平均96.2%。
- 适形指数:质子治疗平均0.6,MLC-based CyberKnife平均0.5(p=0.04)。
- PTV最大剂量均值均为111%(p=0.2),平均剂量均值均为104%。
- 单次治疗时间:质子治疗17分钟,MLC-based CyberKnife 18分钟(p=0.7)。
临床怎么用
- 对于大体积头颈部再程放疗,MLC-based CyberKnife可作为质子治疗的替代选择,尤其需快速剂量跌落保护危及器官时。
- 制定计划时应权衡适形指数与剂量梯度,质子治疗适形性更优,MLC-based CyberKnife梯度更陡。
局限性
- 样本量仅8例,结论需更大规模临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on the feasibility and performance of conventionally fractionated multileaf collimator (MLC)-based robotic stereotactic body re-irradiation of the head and neck region using MLC-based Cyberknife (CK) technology. METHODS: Patients treated for recurrent or second primary head and neck cancer (HNC) with curative proton therapy to a target volume > 30 cm3 between 2011 and 2015 were included. MLC-based CK plans were generated using the CK M6 InCise2 MLC system. Dose statistics from MLC-based CK plans were compared to proton beam therapy (PBT) plans according to the following metrics: target coverage, target homogeneity index, gradient index, Paddick conformity index (CI), prescription isodose volume (PIV), treatment time (tTime) for one fraction as well as doses to organs at risk (OAR). Wilcoxon signed-rank test was used to compare dose metrics. RESULTS: Eight patients were included; the tumor sites included: salivary glands, pharynx (oropharynx, hypopharynx and retropharynx) and sinonasal cavities. Five of 8 patients were treated with multifield optimisation intensity modulated proton therapy, 3 were treated with passive scattering proton therapy. Median dose was 67 Gy (range 60-70) in 32 fractions (range 30-35). The median high-dose planning target volume (PTV) was 45.4 cm3 (range 2.4 - 130.2 cm3) and the median elective PTV was 91.9 cm3 (range 61.2 - 269.7 cm3). Overall, the mean target coverage (mean 98.3% vs. 96.2% for CK vs. PBT, respectively), maximum dose to PTV (mean 111% vs. 111%, p = 0.2) and mean dose to PTV (mean 104% vs. 104%) were similar across modalities. Highly conformal plans were achieved with both modalities, but mean CI was better with PBT (0.5 vs. 0.6 for CK vs. PBT, p = 0.04). Homogeneity and gradient indexes were similar between the 2 modalities; mean tTime with PBT and CK was 17 vs. 18 min, respectively (p = 0.7). Case-based study revealed that CK and PBT plans allowed for excellent sparing of OAR, with some clinical scenarios associated with better performance of CK while others with better performance of PBT. CONCLUSION: Our study has demonstrated the dosimetric performance of large volume head and neck re-irradiation using MLC-based CK in various clinical scenarios. While conformity was generally better achieved with PBT, MLC-based CK allowed for high dose gradient leading to rapid dose drop-off and sparing of OAR. Conventionally fractionated MLC-based CK could be a competitive alternative in large volume head and neck re-irradiation that deserves further investigation in the clinical setting.
引用
- Bahig H, Wang C, Ping Ng S, et al. Conventionally fractionated large volume head and neck re-irradiation using multileaf collimator-based robotic technique: A feasibility study. Clin Transl Radiat Oncol. 2020. PMID: 32715109. doi:10.1016/j.ctro.2020.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。